For following the competition: what moved in each program, several studies read as one move.
- olverembatinib
- BTK Degrader APG-3288
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Ascentage Pharma Group International to watchlistEvery Monday by email · turn it off any timePro · free during the beta